Identification of biomarkers and potential drug targets for esophageal cancer: a Mendelian randomization study

Authors: Chengjun Li, Xiaomeng Cui, Mudan Ren, Yan Yin, Shuixiang He

Source: Scientific Reports, Vol 15, Iss 1, Pp 1-16 (2025)

Subject Terms: Esophageal cancer, Plasma protein, Druggable gene, Mendelian randomization, Drug target, Causality, Medicine, Science

File Description: electronic resource

Relation: https://doaj.org/toc/2045-2322

Access URL: https://doaj.org/article/52eccd74712a4a9086d6df7fd27463f9

Individualized Pooled CRISPR/Cas9 Screenings Identify CDK2 as a Druggable Vulnerability in a Canine Mammary Carcinoma Patient

Authors: Marine Inglebert, Martina Dettwiler, Chang He, Enni Markkanen, Lennart Opitz, Arunasalam Naguleswaran, Sven Rottenberg

Source: Veterinary Sciences, Vol 12, Iss 2, p 183 (2025)

Subject Terms: gene-editing tools, mammary tumor, patient-derived organoid (PDO), epigenome, druggable gene, precision medicine, Veterinary medicine, SF600-1100

File Description: electronic resource

Relation: https://www.mdpi.com/2306-7381/12/2/183; https://doaj.org/toc/2306-7381

Access URL: https://doaj.org/article/f1db190dcdc843699e30385c78f7e095

TBK1, a prioritized drug repurposing target for amyotrophic lateral sclerosis: evidence from druggable genome Mendelian randomization and pharmacological verification in vitro

Authors: Qing-Qing Duan, Han Wang, Wei-Ming Su, Xiao-Jing Gu, Xiao-Fei Shen, Zheng Jiang, Yan-Ling Ren, Bei Cao, Guo-Bo Li, Yi Wang, Yong-Ping Chen

Source: BMC Medicine, Vol 22, Iss 1, Pp 1-16 (2024)

Subject Terms: Amyotrophic lateral sclerosis, Mendelian randomization, Drug repurposing, Druggable gene, TBK1, Medicine

File Description: electronic resource

Relation: https://doaj.org/toc/1741-7015

Access URL: https://doaj.org/article/bdfe3d0b6f5e4857bf7c3919efdcff64

In Silico Strategies for Prospective Drug Repositionings

Contributors: Udrescu, Lucreția, Kurunczi, Ludovic, Bogdan, Paul, Udrescu, Mihai

Subject Terms: COVID-19, drug repurposing, topological data analysis, persistent Betti function, SARS-CoV-2, network-based pharmacology, combination therapy, nucleoside GS-441524, fluoxetine, synergy, antidepressant, natural compounds, QSAR, molecular docking, drug repositioning, UK Biobank, vaccine, LC-2/ad cell line, drug discovery, docking, MM-GBSA calculation, molecular dynamics, cytotoxicity assay, GWAS, multiple sclerosis, oxidative stress, repurposing, ADME-Tox, bioinformatics, complex network analysis, modularity clustering, ATC code, hidradenitis suppurativa, acne inversa, transcriptome, proteome, comorbid disorder, biomarker, signaling pathway, druggable gene, drug-repositioning, MEK inhibitor, MM/GBSA, Glide docking, MD simulation, MM/PBSA, single-cell RNA sequencing, pulmonary fibrosis, biological networks, p38α MAPK, allosteric inhibitors, in silico screening, computer-aided drug discovery, network analysis, psychiatric disorders, medications, psychiatry, mental disorders, toxoplasmosis, Toxoplasma gondii, in vitro screening, drug targets, drug-disease interaction, target-disease interaction, DPP4 inhibitors, lipid rafts, Medicine and Nursing, Manufacturing industries

File Description: image/jpeg

Access URL: https://directory.doabooks.org/handle/20.500.12854/96611
https://mdpi.com/books/pdfview/book/6556

In Silico Strategies for Prospective Drug Repositionings

Contributors: Udrescu, Lucreția, Kurunczi, Ludovic, Bogdan, Paul, Udrescu, Mihai

Subject Terms: COVID-19, drug repurposing, topological data analysis, persistent Betti function, SARS-CoV-2, network-based pharmacology, combination therapy, nucleoside GS-441524, fluoxetine, synergy, antidepressant, natural compounds, QSAR, molecular docking, drug repositioning, UK Biobank, vaccine, LC-2/ad cell line, drug discovery, docking, MM-GBSA calculation, molecular dynamics, cytotoxicity assay, GWAS, multiple sclerosis, oxidative stress, repurposing, ADME-Tox, bioinformatics, complex network analysis, modularity clustering, ATC code, hidradenitis suppurativa, acne inversa, transcriptome, proteome, comorbid disorder, biomarker, signaling pathway, druggable gene, drug-repositioning, MEK inhibitor, MM/GBSA, Glide docking, MD simulation, MM/PBSA, single-cell RNA sequencing, pulmonary fibrosis, biological networks, p38α MAPK, allosteric inhibitors, in silico screening, computer-aided drug discovery, network analysis, psychiatric disorders, medications, psychiatry, mental disorders, toxoplasmosis, Toxoplasma gondii, in vitro screening, drug targets, drug-disease interaction, target-disease interaction, DPP4 inhibitors, lipid rafts, Medicine and Nursing, Manufacturing industries

File Description: image/jpeg

Access URL: https://directory.doabooks.org/handle/20.500.12854/95899
https://mdpi.com/books/pdfview/book/6556

Clinical implications of next‐generation sequencing‐based panel tests for malignant ovarian tumors

Authors: Keiko Saotome, Tatsuyuki Chiyoda, Eriko Aimono, Kohei Nakamura, Shigeki Tanishima, Sachio Nohara, Chihiro Okada, Hideyuki Hayashi, Yuka Kuroda, Hiroyuki Nomura, Nobuyuki Susumu, Takashi Iwata, Wataru Yamagami, Fumio Kataoka, Hiroshi Nishihara, Daisuke Aoki

Source: Cancer Medicine, Vol 9, Iss 20, Pp 7407-7417 (2020)

Subject Terms: Actionable gene alteration, Clinical sequencing, Druggable gene alteration, Ovarian cancer, Precision medicine, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/2045-7634

Access URL: https://doaj.org/article/2d19c02abb76489399e586dae50834c3

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.